These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29504152)

  • 1. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.
    Attia D; El Saeed K; Elakel W; El Baz T; Omar A; Yosry A; Elsayed MH; Said M; El Raziky M; Anees M; Doss W; El Shazly Y; Wedemeyer H; Esmat G
    Aliment Pharmacol Ther; 2018 May; 47(9):1296-1305. PubMed ID: 29504152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
    Yosry A; Gamal Eldeen H; Medhat E; Mehrez M; Zayed N; Elakel W; Abdelmoniem R; Kaddah M; Abdelaziz A; Esmat G; El-Serafy M; Doss W
    J Med Virol; 2019 Apr; 91(4):668-676. PubMed ID: 30549048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
    Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
    Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
    Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y
    Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
    Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
    Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
    Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
    J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
    Tsai WL; Wang CF; Cheng JS; Chen WC; Bair MJ; Lo CC
    PLoS One; 2020; 15(1):e0227424. PubMed ID: 31923251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
    Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
    Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
    Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
    PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
    BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
    Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
    Wei JY; Lin DN; Wu ZB; Zhu JY; Zhao ZX; Mei YY; Lin CS; Zhang J; Zhang XH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):933-939. PubMed ID: 30669787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.